摘要
目的评估抗gp210抗体对原发性胆汁性肝硬化(PBC)患者诊断、治疗和预后的意义。方法分析83例PBC患者的资料,随访观察临床表现、肝功能、PBC相关自身抗体和熊去氧胆酸(UDCA)治疗反应。结果抗gp210阳性组清蛋白平均水平明显低于阴性组(P<0.05),总胆红素(TBIL)平均水平高于阴性组,差异无统计学意义。随访阳性组肝衰竭发生率高于阴性组(P<0.05);UDCA治疗1年患者谷丙转氨酶(ALT)、碱性磷酸酶(ALP)、γ-谷氨酰转肽酶(γ-GT)平均水平明显低于初诊(P<0.05),抗gp210阳性患者生化指标间差异无统计学意义。结论抗gp210可作为预后指标;UDCA能有效改善患者的生化指标,长期应用延缓疾病进展。
Objective To evaluate the clinical significance of anti-gp210 antibodies for diagnosing and treating patients with Primary brimary cirrhosis（PBC）.Methods A total of 83 patients with PBC were studied.The clinical manifestations,liver function tests,PBC associated autoantibodies and treatment rsponse with UDCA were followed for one year.Results Compared with anti-gp210 antibody negative group,the mean level of serum albumin was significantly lower that in anti-gp210 antibody positive group,t the hepatic failure rate was significantly higher in anti-gp210 antibodies positive group than that in anti-gp210 antibodies negative group（P〈0.05）.Mean levels of serum alanine transarninase（ALT）、alkaline phosphatase（ALP）、glutamyltranspeptidase（γ-GT） were significantly decreased after one year treatment with UDCA but not statistically significant in anti-gp210 positive patients.Conclusion Anti-gp210 antibody can make a prognostic indicator;UDCA can improve biochemical indicators of patients effectively,Long-term application can postpone progress of PBC.
出处
《安徽医学》
2010年第7期711-713,共3页
Anhui Medical Journal
基金
安徽高校省级自然科学研究项目(2009KJB072)
